Coagulation pathway R-HSA-9769740: Genes & Research

The coagulation pathway (Reactome R-HSA-9769740) is the biological process by which blood forms a stable clot at sites of vascular injury while remaining fluid under normal conditions. Rather than a simple linear cascade, the modern cell-based model describes overlapping initiation, amplification and propagation phases that take place on the membranes of tissue factor-bearing cells and activated platelets. This spatial and cellular organization ensures that thrombin generation is localized, self-limiting and tightly regulated by endogenous anticoagulants. For researchers, the coagulation pathway is a paradigm of proteolytic signaling, membrane-dependent enzyme complex assembly and feedback control, and it is directly relevant to bleeding disorders, thrombosis, sepsis and cardiovascular disease. Understanding which genes and protein complexes drive each phase is essential for designing targeted experiments, interpreting coagulation assays and developing therapeutics. What Is the Coagulation pathway Pathway? R-HSA-9769740 is the Reactome module for the human coagulation pathway, modeled as a cell-based process. It begins with the initiation phase, in which activated tissue factor (TF) binds factor VIIa (FVIIa) and the TF:FVIIa complex generates a small amount of thrombin on TF-bearing cells such as fibroblasts and pericytes. In the amplification phase, this thrombin activates factor XI, factor VIII and factor V on the platelet surface, and activated platelets expose phosphatidylserine to provide a membrane surface for assembly of the tenase (FIXa:FVIIIa) and prothrombinase (FXa:FVa) complexes. The propagation phase on activated platelets produces a large thrombin burst via FXa:FVa-catalyzed cleavage of prothrombin. Finally, thrombin converts soluble fibrinogen into fibrin, which polymerizes and is crosslinked by thrombin-activated factor XIII to stabilize the platelet plug. The pathway also includes natural anticoagulants such as TFPI, protein C, protein S, thrombomodulin and antithrombin III that prevent excessive clotting.

R-HSA-9769740 is the Reactome module for the human coagulation pathway, modeled as a cell-based process. It begins with the initiation phase, in which activated tissue factor (TF) binds factor VIIa (FVIIa) and the TF:FVIIa complex generates a small amount of thrombin on TF-bearing cells such as fibroblasts and pericytes. In the amplification phase, this thrombin activates factor XI, factor VIII and factor V on the platelet surface, and activated platelets expose phosphatidylserine to provide a membrane surface for assembly of the tenase (FIXa:FVIIIa) and prothrombinase (FXa:FVa) complexes. The propagation phase on activated platelets produces a large thrombin burst via FXa:FVa-catalyzed cleavage of prothrombin. Finally, thrombin converts soluble fibrinogen into fibrin, which polymerizes and is crosslinked by thrombin-activated factor XIII to stabilize the platelet plug. The pathway also includes natural anticoagulants such as TFPI, protein C, protein S, thrombomodulin and antithrombin III that prevent excessive clotting.

The coagulation pathway is essential for hemostasis, and its dysregulation underlies both bleeding and thrombotic disease. Because thrombin generation is amplified through positive feedback loops and simultaneously restrained by multiple anticoagulant systems, even small changes in factor levels or activity can shift the balance toward hemorrhage or pathologic thrombosis. This makes the pathway a central topic in hematology, critical care, cardiovascular medicine and drug development, and it explains why coagulation testing and factor-specific assays remain core laboratory tools.

The following genes and entities from Reactome R-HSA-9769740 represent the core coagulation factors, receptors, inhibitors and pharmacologic agents that define the pathway.

Coagulation is regulated by multiple endogenous inhibitors and feedback loops that prevent excessive clot formation. TFPI forms a quaternary complex with FXa, FVIIa and TF to restrict initiation. The protein C pathway, activated by the thrombin:thrombomodulin complex on endothelial cells, deactivates FVa and FVIIIa with protein S as a cofactor. Antithrombin III (SERPINC1), bound to heparan sulfate, forms complexes with thrombin, FXa and FXIa to limit propagation. Additional inhibitors in the pathway include SERPIND1, SERPINA5 and SERPINE2, which contribute to protease regulation. Positive feedback loops, in which thrombin activates FXI, FVIII and FV, are balanced by these inhibitors to keep thrombin generation localized.

Deficiencies or dysfunction of coagulation factors such as FVIII, FIX, FXI, FV, FX and prothrombin cause bleeding disorders of varying severity. Isolated prolongation of activated partial thromboplastin time can indicate defects in the intrinsic or common pathway and is not always associated with bleeding risk, making careful interpretation essential. The cell-based model helps explain why factor activity levels correlate imperfectly with clinical bleeding phenotypes.

Excessive or mislocalized thrombin generation contributes to pathologic thrombosis, and natural anticoagulant deficiencies such as protein C, protein S or antithrombin III deficiency predispose to thrombophilia. Cardiovascular risk burden has been associated with changes in coagulation pathway parameters in apparently healthy individuals, supporting a link between cardiovascular disease and coagulation activation. Anticoagulant drugs targeting thrombin and FXa are widely used to prevent and treat thrombotic events.

Sepsis is frequently accompanied by activation of coagulation and suppression of fibrinolysis, contributing to disseminated intravascular coagulation and organ dysfunction. The interplay between inflammation and coagulation in sepsis involves tissue factor expression and downregulation of natural anticoagulant pathways. This makes coagulation pathway genes relevant biomarkers and therapeutic targets in critical care research.

RNA-seq can quantify expression of coagulation pathway genes such as F2, F5, F8, F9, F10, PROC and SERPINC1 across cell types and conditions, while proteomic approaches can measure factor protein levels and post-translational modifications. These methods help identify which components of R-HSA-9769740 are active in a given biological context.

Prothrombin time (PT), activated partial thromboplastin time (aPTT) and specific factor activity assays are standard tools for measuring pathway function and diagnosing defects. These assays can be applied to conditioned media from engineered cell models to test whether CRISPR edits alter thrombin generation.

Fluorogenic thrombin-generation assays and reporter constructs can quantify FXa:FVa and tenase complex activity in cell-based systems. Such assays are useful for testing the effect of point mutations or knockouts in factors such as F2, F5, F8, F9 and F10.

Fluorescence microscopy of tagged coagulation factors and phosphatidylserine probes can visualize assembly of tenase and prothrombinase complexes on activated cell membranes. These approaches are valuable for studying the spatial organization of the cell-based coagulation model.

Functional dissection of the coagulation pathway requires precise, reproducible genome engineering across multiple cell types, from hepatocytes to endothelial cells and platelets. EDITGENE provides end-to-end CRISPR services that support every stage of coagulation research, from gene knockout and point-mutation modeling to knock-in reporters and overexpression systems.

The coagulation pathway (R-HSA-9769740) provides a comprehensive, cell-based framework for understanding how thrombin generation and fibrin formation are initiated, amplified and controlled. Its genes and protein complexes are central to hemostasis and to diseases ranging from hemophilia to thrombosis and sepsis-associated coagulopathy. CRISPR-based cell models offer a powerful approach to test the function of individual coagulation factors and their regulators in a physiologically relevant context. By combining pathway knowledge with precise genome engineering, researchers can accelerate the discovery of new diagnostic and therapeutic strategies for coagulation disorders.